Cost-effectiveness of dabigatran etexilate in Canada for the primary prevention of venous thromboembolism in patients undergoing total hip replacement surgery

被引：0
|
作者：
Bradley-Kennedy, C. [1 ]
Wolowacz, S. E. [2 ]
Roskell, N. S. [3 ]
Plumb, J. M. [4 ]
机构：
[1] Boehringer Ingelheim Ltd, Hlth Econ & Outcomes Res, Burlington, ON, Canada
[2] RTI Hlth Solut Ltd, Hlth Econ, Manchester, England
[3] RTI Hlth Solut Ltd, Biometr, Manchester, England
[4] Boehringer Ingelheim GmbH & Co KG, Hlth Econ & Outcomes Res, Ingelheim, Germany
来源：
JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2009年 / 7卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PP-WE-470
引用
收藏
页码：786 / 786
页数：1
相关论文
共 50 条
  • [31] ESTIMATING THE BUDGET IMPACT OF DABIGATRAN ETEXILATE IN THE PRIMARY PREVENTION OF VENOUS THROMBOEMBOLISM FOLLOWING TOTAL HIP OR KNEE REPLACEMENT SURGERY: AN INTERACTIVE MODEL FOR LOCAL HEALTH ECONOMIES IN THE UK
    Robinson, P.
    Zah, V
    VALUE IN HEALTH, 2008, 11 (06) : A389 - A389
  • [32] Type of anaesthesia did not affect the efficacy and safety profile of dabigatran etexilate compared with enoxaparin for primary venous thromboembolism prevention following total knee or hip replacement surgery
    Rosencher, N.
    Noack, H.
    Feuring, M.
    Clemens, A.
    Friedman, R.
    Eriksson, B., I
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 989 - 989
  • [33] COST-EFFECTIVENESS OF RIVAROXABAN VERSUS ENOXAPARIN FOR PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL HIP AND KNEE REPLACEMENT IN EUROPE
    Monreal, M.
    Ryttberg, L.
    Diamantopoulos, A.
    Lees, M.
    Negrini, C.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 50 - 51
  • [34] EFFICACY AND SAFETY PROFILE OF 220 MG DABIGATRAN ETEXILATE IN PATIENTS UNDERGOING TOTAL HIP OR KNEE REPLACEMENT SURGERY WITH A HISTORY OF STROKE, TRANSIENT ISCHAEMIC ATTACK OR VENOUS THROMBOEMBOLISM
    Dahl, O. E.
    Francis, C.
    Kurth, A. A.
    Rosencher, N.
    Feuring, M.
    Noack, H.
    Clemens, A.
    Eriksson, B. I.
    Caprini, J. A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 179 - 180
  • [35] Dabigatran Etexilate for the Prevention of Venous Thromboembolism in Patients Undergoing Elective Hip or Knee SurgeryA NICE Single Technology Appraisal
    Michael Holmes
    Christopher Carroll
    Diana Papaioannou
    PharmacoEconomics, 2012, 30 (2) : 137 - 146
  • [36] Pharmacoeconomics of dabigatran etexilate for prevention of thromboembolism after joint replacement surgery
    Wolowacz, Sorrel E.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2011, 11 (01) : 9 - 25
  • [37] Cost-effectiveness of rivaroxaban versus heparins for prevention of venous thromboembolism after total hip or knee surgery in Sweden
    Ryttberg, Lars
    Diamantopoulos, Alex
    Forster, Fiona
    Lees, Michael
    Fraschke, Anina
    Bjorholt, Ingela
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2011, 11 (05) : 601 - 615
  • [38] PROPHYLAXIS FOR VENOUS THROMBOEMBOLISM IN HIP FRACTURE SURGERY - TOTAL COSTS AND COST-EFFECTIVENESS IN THE NETHERLANDS
    MOL, WEM
    EGBERTS, TCG
    PHARMACOECONOMICS, 1994, 5 (01) : 48 - 55
  • [39] Cost-effectiveness of rivaroxaban for prevention of venous thromboembolism (VTE) after total hip or knee replacement (THR, TKR) in the USA
    Kwong, L.
    Duran, A.
    Diamantopoulos, A.
    Sengupta, N.
    Lees, M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 787 - 787
  • [40] Standard dose of dabigatran etexilate in patients undergoing total hip or knee replacement surgery who are predisposed to post-operative venous thromboembolism: effective and good safety profile
    Dahl, O. E.
    Francis, C.
    Kurth, A.
    Rosencher, N.
    Feuring, M.
    Noack, H.
    Eriksson, B., I
    Caprini, J. A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 990 - 990
12345